Product Images Dofetilide

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Dofetilide NDC 42291-411 by Avkare, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

411 60 125mcg

411 60 125mcg

412 60 250mcg

412 60 250mcg

413 60 500mcg

413 60 500mcg

Chemical Structure - dc 1

Chemical Structure - dc 1

figure 1 - dc 2

figure 1 - dc 2

This is a table presenting the Mean Change from Baseline QTc at Day 1 and Day 23 (Steady State) in relation to the Mean Plasma Dofetilide Concentration (ng/mL). No further information is available.*

figure 2 - dc 3

figure 2 - dc 3

figure 3 - dc 4

figure 3 - dc 4

figure 4 - dc 5

figure 4 - dc 5

This is a chart depicting the p-values (probability values) obtained from performing Log Rank Tests on patients who were given different doses of Dofetilide. The doses were 125 mg, 250 mg, and 500 mg, administered twice a day (BID). The x-axis shows the time elapsed in months and the y-axis shows the p-value obtained from the test. The chart shows that the patients who were given higher doses of Dofetilide had significantly better outcomes compared to the group that was given the lower dose.*

flow chart - dc 6

flow chart - dc 6

This text provides instructions for the use of dofetilide in patients on telemetry. It includes guidelines for checking baseline QTc and calculating creatinine clearance to determine dosage. It also outlines the appropriate dosages of dofetilide based on the patient's creatinine clearance. The text warns against using dofetilide if the patient's QTc exceeds 440 msec or if their creatinine clearance is less than 20 mL/min. Additionally, it recommends checking QTc levels 2-3 hours after the first dose and adjusting dosage as necessary to avoid excessive increases in QTc. If at any time after the second dose the QTc increases >500 msec, dofetilide should be discontinued.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.